Pharmacy2Home/LandiCom Holding LTD
Compliance Profile
"Risk Warning: Confirming the inclusion of Pharmacy2Home/LandiCom Holding LTD (Entity) in global watchlists, including FDA WARNING LETTER. Transactions or engagement may require review."
Banking Impact
Records on FDA WARNING LETTER can trigger enhanced due diligence, compliance holds, counterparty review and documentation requests from banks, investors or procurement teams.
Legal Status
The record should be reviewed against the original source list, jurisdiction and date of publication before decisions are made. Escalation may be required for procurement, onboarding or investor diligence.
Official Source Metadata
Source: FDA Warning Letters| Full Legal Name | Pharmacy2Home/LandiCom Holding LTD |
| Source Records | FDA WARNING LETTER |
| Enforcement Type | FDA Warning Letters |
| Identifiers | 2022-02-03 / Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19) |
| Risk Topics | reg.action, reg.warn, sector.medical |
| Official Source | View source record |
Compliance Context Review
Independent Risk Assessment
SIC Group prepares source-backed risk context, exposure memos, and remediation pathways for entities seeking to clarify a public record or counterparty signal.